Dyansys Inc. has embarked on the widespread commercialization of Portable ANSiscope® (for family physicians).

We are now shipping product. The immediate applications are in diabetes. Enough research has been done (over the last 20 years) in this application, by the medical community to prove the utility and the necessity of a measurement of the Autonomic Nervous System. The ADA (American Diabetes Association) has mentioned this in its standards of medical published in Jan 2006.

There are many applications of the product in other areas of medicine also since the autonomic nervous system plays a large but not well-understood role in the healthy functioning of the human body. The company expects that the availability of the product in the market will unlock many further applications.

The next applications we intend to focus on are anesthesia and cardiology, where it could be used to dose analgesic drugs and also to identify people at high risk respectively. This information would be very useful to doctors to identify the right patients for further therapy such as implantation of a cardioverter defibrillator. There is enough research to prove that this is possible. We need to work on developing the application for our product. This is potentially a huge application.

The Portable ECScope

In the meantime, we have introduced our second new product, the Portable ECScope. This is built on the ANSiscope platform and represents "out of the box" thinking in the design of ECG monitors. We are again starting to ship product in India and expand sales all over India within the next quarter. The initial customer response has been extremely encouraging.

Market Strategy

We are pricing the products (especially Portable ANSiscope®) such that they are affordable to the medical community in every region that we operate. The usefulness and affordability of our products will give them the potential to become fundamental medical instruments.

We would be interested in talking to potential investors who would like to be part of the growth of a medical instrumentation company with some unique technology (US patents #7, 092, 849 issued on Aug 15th, 2006) and participating in very high growth markets at very low risk. The entire technological risk is behind us.

Further investments will be used to fund the sales & marketing efforts of the company along with some investment in the development of next generation products and further new applications for ANS monitoring.

The management is also planning on a liquidity event in the next 3-4 years. This is a unique opportunity to invest in health care company without increasing the long cycle time for health care investment.

Interested parties may contact the company by email at the following address: investors@dyansys.com